Prize Winners

Curriculum Vitae

Doctor of Medicine and specialist in Cardiology. He is currently the Scientific Director of the National Center for Cardiovascular Research (CNIC) and also practices at the Jiménez Díaz Foundation in Madrid. His research has focused on cardiovascular diseases, especially acute myocardial infarction, heart failure, and the prevention of atherosclerotic disease. Throughout his career, he has combined basic, translational, and clinical research to improve the diagnosis, prevention, and treatment of cardiovascular diseases. His work has made a decisive contribution to understanding the biological mechanisms involved in cardiac damage after a heart attack and to developing new therapeutic strategies that have improved the care of millions of patients worldwide. Among his most significant contributions is his leadership of large international clinical trials that have transformed the use of beta-blockers after myocardial infarction. His research has demonstrated which patients truly benefit from these treatments and which do not, leading to a paradigm shift in clinical practice and in the main international cardiology guidelines.
He has also driven significant advances in the fields of heart failure, cardio-oncology, and cardiovascular imaging techniques. His research has enabled the development of new strategies to prevent cardiac damage associated with cancer treatments and has contributed to the design of innovative diagnostic tools, including ultrafast cardiac magnetic resonance imaging systems with the potential to expand access to these technologies for millions of people. Author of more than 420 scientific publications and one of the most cited researchers in the world in his field, he has led numerous international projects and played a prominent role in the development of the European Society of Cardiology's clinical guidelines, which guide cardiovascular treatment worldwide.

Jury ruling

The jury of the Rei Jaume I Prizes has unanimously decided to award Dr. Borja Ibáñez in Clinical Research and Public Health for his contributions to improving clinical care for patients with heart disease through the development of seminal clinical trials for the treatment of ischemic heart disease and heart failure, as well as his work in education and research on the treatment and prevention of cardiovascular disease.